Скачать или смотреть TKI Discontinuation in CML Explained | Are You Meeting the Criteria? by Dr. Karthik K

Can CML patients ever safely stop TKIs?

In this conceptual session, we simplify the criteria for TKI discontinuation in Chronic Myeloid Leukemia (CML) — including eligibility, duration of deep molecular response, and monitoring protocols as per ELN and NCCN 2022–2023 guidelines.

Understand what defines a sustained MR4 or MR4.5, why BCR-ABL1 transcript monitoring is essential, and when restarting therapy is recommended.

Perfect for residents and clinicians who want to master the evolving concept of treatment-free remission (TFR) in CML.

🔔 Don’t forget to subscribe for more medical education content.

Follow us on:

  / 61565429673115  
instagram.com/conceptual_medicine_/?hl=en

#CML #TKIDiscontinuation #TreatmentFreeRemission #Hematology #Oncology #ConceptualMedicine #eConceptual #Leukemia #ChronicMyeloidLeukemia #Imatinib #Dasatinib #Nilotinib #ExamPreparation #MedicalEducation